CAS: 80530-63-8; Picolinamide Hydrate

该化合物是一种化学化合物,主要因其作为药剂的作用而得到承认,被归类为非类固醇抗炎药物(NSAID),并因其抗板和血管血管功能而闻名.该物质经常用于治疗心血管病症,特别是防止血压形成.就其物理特征而言,硅酰胺单水合物一般是白到白的晶状粉,在标准储存条件下,在水和展览中具有稳定性.单水分形式表明存在一种与每一种分子硅酰胺相关的水分子,可影响其溶性和生物利用率.该化合物的行动机制涉及抑制聚变色素A2合成,从而减少聚积量.与许多药剂一样,有必要考虑其在临床环境中使用的剂量,潜在副作用和与其他药物的相互作用.

结构式图片

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2003050305-A1
    优先权日:2000-05-22
    标题:Thromboxane inhibitors, compositions and methods of use
    发明人:TEJADA INIGO SAENZ DE
    摘要:The present invention describes methods for treating or preventing sexual dysfunctions in males and females, and for enhancing sexual responses in males and females by administering a therapeutically effective amount of at least one thromboxane inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The male or female may preferably be diabetic. The present invention also provides novel compositions comprising at least one thromboxane inhibitor, and, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and, optionally, at least one therapeutic agent, such as, vasoactive agents, nonsteroidal antiinflanmmatory compounds (NSAIDs), selective cyclooxygenase-2 (COX-2) inhibitors, anticoagulants, angiotensin converting enzymes (ACE) inhibitors, angiotensin II receptor antagonists, renin inhibitors, and mixtures thereof. The present invention also provides methods for treating or preventing ischemic heart disorders, myocardial infarction, angina pectoris, stroke, migraine, cerebral hemorrhage, cardiac fatalities, transient ischaemic attacks, complications following organ transplants, coronary artery bypasses, angioplasty, endarterectomy, atherosclerosis, pulmonary embolism, bronchial asthma, bronchitis, pneumonia, circulatory shock of various organs, nephritis, graft rejection, cancerous metastases, pregnancy-induced hypertension, preeclampsia, eclampsia, thrombotic and thromboembolic disorders, intrauterine growth, gastrointestinal disorders, renal diseases and disorders, disorders resulting from elevated uric acid levels and dysmenorrhea, and for inhibiting platelet aggregation or platelet adhesion or relaxing smooth muscles.

    专利号:EP-1242068-A1
    优先权日:1999-10-29
    标 题:Endogenous nitric oxide synthesis under conditions of low oxygen tension

    专利号:WO-0132167-A1
    优先权日:1999-10-26
    标题:Endogenous nitric oxide synthesis under conditions of low oxygen tension

    专利号:EP-1242068-A4
    优先权日:1999-10-29
    标 题:ENDOGENIC NITROGEN OXYDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN PARTICULAR PRESSURE

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1016/j.bbrc.2023.08.050
    摘要:Ikeda Y, Davis MI, Sumita K, Zheng Y, Kofuji S, Sasaki M, Hirota Y, Pragani R, Shen M, Boxer MB, Takeuchi K, Senda T, Simeonov A, Sasaki AT. Multimodal action of KRP203 on phosphoinositide kinases in vitro and in cells. Biochemical and Biophysical Research Communications. 2023 Oct;679():116–21. doi: 10.1016/j.bbrc.2023.08.050.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知